微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 49.44% | -18.12% | -0.27% | 75/159 | -2.21% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 49.57% | -14.98% | 10.69% | 73/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 44.78% | -15.34% | -22.53% | 84/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 57.8% | -7.77% | -4.27% | 55/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 60.38% | -6.15% | 3.56% | 51/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 58.3% | -12.19% | 10.22% | 58/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 52.9% | -12.94% | -15.6% | 69/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 62.67% | -3.05% | -2.58% | 45/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 64.33% | -7.19% | -3.11% | 41/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 66.4% | -3.11% | 9.28% | 40/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 60.76% | -6.01% | -6.01% | 53/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 64.65% | -6.64% | -6.74% | 49/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 69.32% | 1.14% | 1.15% | 38/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 68.53% | -0.18% | 6.01% | 45/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 64.65% | 1.88% | -6.64% | 46/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 69.24% | 4.89% | 1.02% | 45/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 68.54% | 7.28% | -0.17% | 37/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 68.65% | 9.83% | 8.2% | 41/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 63.45% | 2% | -3.88% | 42/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 66.01% | 8.36% | 3.32% | 47/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 63.89% | 2% | 2.21% | 46/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 62.51% | 2% | 2.61% | 47/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 60.92% | 2% | 2% | 55/159 | -1222.98% | 多瑞医药 | 95.59% | 行业排名> |